(BN) Brookfield - Ratings and Ratios

Exchange: NYSE • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA11271J1075

BN: Real Estate, Renewable Energy, Infrastructure, Investment Management

Brookfield Corporation (NYSE:BN) is a leading global alternative asset manager and Real Estate Investment Trust (REIT) specializing in real estate, renewable power, infrastructure, and private equity. With over $750 billion in assets under management, Brookfield is one of the largest players in the alternative investment space. The firm manages a diverse range of public and private investment vehicles, catering to both institutional and retail clients. Brookfields investment strategy focuses on acquiring high-quality, large-scale assets across geographies and sectors, leveraging its own capital alongside that of its investors. This approach allows the firm to maintain control and flexibility in its investments.

In private equity, Brookfield targets underperforming or distressed assets, focusing on sectors with significant real asset exposure, such as industrials, infrastructure, and business services. The firms private equity portfolio includes investments in automotive manufacturing, healthcare infrastructure, and energy distribution. Brookfield also has a strong presence in renewable energy, owning and operating wind farms, solar projects, and hydroelectric facilities. Its real estate investments span office, retail, and logistics properties in major global cities. The firms investment horizon typically ranges from four to ten years, with a focus on long-term value creation through operational improvements and strategic restructuring. Brookfields global footprint includes offices in North America, Europe, Asia, and South America, enabling it to identify and capitalize on investment opportunities worldwide.

3-Month Forecast

Based on the technical and fundamental data, Brookfield Corporations stock is expected to face short-term headwinds. The last price of $49.70 is below its 20-day and 50-day moving averages ($50.77 and $53.81, respectively), indicating downward momentum. The stock may encounter resistance at the 200-day moving average ($53.08). The average true range (ATR) of 2.42 suggests moderate volatility over the next three months.

From a fundamental perspective, Brookfields high P/E ratio (149.16) compared to its forward P/E (12.15) indicates potential overvaluation in the near term. However, the low price-to-sales (P/S) ratio of 0.85 and the firms strong market position in alternative assets may signal undervaluation. The return on equity (RoE) of 1.27% reflects modest profitability, which could impact investor sentiment. Overall, the stock is likely to remain under pressure in the short term but may present long-term value as the market recalibrates its expectations.

Additional Sources for BN Stock

BN Stock Overview

Market Cap in USD 75,704m
Sector Financial Services
Industry Asset Management
GiC Sub-Industry Asset Management & Custody Banks
IPO / Inception 1983-12-30

BN Stock Ratings

Growth Rating 61.4
Fundamental 14.4
Dividend Rating 18.5
Rel. Strength 8.56
Analysts 3.78/5
Fair Price Momentum 46.14 USD
Fair Price DCF -

BN Dividends

Dividend Yield 12m 0.65%
Yield on Cost 5y 1.35%
Annual Growth 5y -3.73%
Payout Consistency 95.8%

BN Growth Ratios

Growth Correlation 3m -87.3%
Growth Correlation 12m 73.9%
Growth Correlation 5y 57.9%
CAGR 5y 15.46%
CAGR/Max DD 5y 0.37
Sharpe Ratio 12m 1.30
Alpha 19.11
Beta 1.474
Volatility 60.27%
Current Volume 3771.8k
Average Volume 20d 3631.9k
What is the price of BN stocks?
As of April 24, 2025, the stock is trading at USD 50.05 with a total of 3,771,779 shares traded.
Over the past week, the price has changed by +1.44%, over one month by -9.58%, over three months by -14.91% and over the past year by +27.22%.
Is Brookfield a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Brookfield is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 14.35 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BN as of April 2025 is 46.14. This means that BN is currently overvalued and has a potential downside of -7.81%.
Is BN a buy, sell or hold?
Brookfield has received a consensus analysts rating of 3.78. Therefor, it is recommend to hold BN.
  • Strong Buy: 2
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • Strong Sell: 1
What are the forecast for BN stock price target?
According to ValueRays Forecast Model, BN Brookfield will be worth about 52.1 in April 2026. The stock is currently trading at 50.05. This means that the stock has a potential upside of +4%.
Issuer Forecast Upside
Wallstreet Target Price 66.8 33.4%
Analysts Target Price 67.9 35.6%
ValueRay Target Price 52.1 4%